Medibeacon® transdermal gfr system receives fda approval to assess kidney function

New york, jan. 17, 2025 (globe newswire) -- innovate corp. (nyse: vate) (“innovate” or the “company”) announced today that the u.s. food and drug administration (fda) has approved the medibeacon® tgfr for the assessment of kidney function in patients with normal or impaired renal function.
GFR Ratings Summary
GFR Quant Ranking